In association with:
SwissCham Shanghai is delighted to invite you to:
Thursday, November 29, 2018
18:30 – 21:00
Dear Members and Friends of SwissCham,
During the last years, Chinese government adhered to the principles of encouragement and support for foreign companies investing in Chinese Mainland by Merger & Acquisition (M&A). The National Development and Reform Commission, Ministry of Commerce, etc., simplified the management procedures for foreign capital M&A transactions accordingly.
For many European companies, it always remains as an option for the purpose of restructuring or expansion to acquire Chinese small and medium enterprises (SMEs). However, before the initiation of an M&A transaction in China, have you clarified the following questions:
- What is the most appropriate deal structure?
- How to choose applicable law/jurisdiction?
- How to manage and protect IPs during and after the acquisition of the Chinese SME?
- What are the crucial aspects of the financial due diligence of the Chinese SME?
- What should be my negotiation strategy against a Chinese SME?
- What are the major differences between a Chinese SME target and a European target?
Your SwissCham Team
About the Speakers:
||Dr. Leonardo Cereghetti – Kellerhals Carrard
Dr. Leonardo Cereghetti has a long and vast experience in the areas of M&A, corporate finance and banking as well as real estate. Dr Cereghetti studied at the University of St. Gallen focusing on legal and business administration and graduated 1989 as lic.iur. HSG. After having served as a research fellow at the University and a three months’ stay at Harvard law school to complete his doctor thesis focusing on disclosure obligations under corporate and securities laws, Dr. Cereghetti graduated as Dr.iur HSG in 1995. He started to work as a lawyer in 1993, first in the tax department of PricewaterhouseCoopers and successively with a business law firm in Zurich, where he became a partner in 2000. Since 2006 Dr Cereghetti is a partner at Kellerhals Carrard in Zurich. In the last 12 months, Dr. Cereghetti has been leading a legal team in various M&A transactions in real estate and the finance area. Currently, he is advising in connection with the setup of a venture structure in the medical industry. Dr. Cereghetti works in German, English, French and Italian.
||Mr. Cheng Chen – Kellerhals Carrard
Cheng CHEN graduated from University of Fribourg (lic. iur.) 2006 in Switzerland. He is very probably the only lawyer admitted to the PRC Bar, who has a complete legal education in Switzerland and fully understands Swiss culture including Swiss German. During his practicing experience of nearly 13 years, he provided legal services in corporate law, mergers and acquisitions, and the related litigation and arbitration for a number of European companies, especially Swiss companies. Meanwhile, as the only lawyer recommended by the Embassy of China in Switzerland, he has assisted many Chinese state-owned and private companies in their investments and acquisitions in Switzerland.
|Dr. Guojian Xu – Boss & Young
Dr. Xu Guojian is the Director of the Boss & Young, attorneys-at-law, specializing in cross-border M&A, foreign investment and international commercial arbitration. Dr. Xu has completed some influential M&A programs, such as the acquisition of Shandong Airlines by Air China Group in 2003 and the acquisition of Wuxi Sicomm by CML in 2016, etc. He was nominated by AsiaLawprofile as Leading Lawyer in Corporate/M&A in 2016 and was selected by China Business Law Journal as China Top 100 Lawyers in 2016 and 2017. Dr. Xu was also appointed as “Vertrauensanwalt” by the Consulate General of Switzerland in Shanghai.
||Mr. Manfred Ortmaier – DKSH Shanghai
Originally from Austria, Manfred Ortmaier graduated from the Stockholm School of Economics with a Masters in Corporate Finance and a Masters in International Management CEMS. During his studies, he has also spent an exchange semester at Tsinghua University in Beijing.
Manfred started his career at DKSH as Assistant to the Chief Operating Officer, where he was involved in the divestment of two pharmaceutical brands in China and an acquisition of a Chinese online distributor. Manfred then spent two years in business development to grow the DKSH healthcare business and acquired new client relationships in China, before moving back to finance. In his current position, he was part of the M&A team to divest the CHF 300m DKSH healthcare distribution business, which was successfully closed earlier this year.
Date & Time （日期及时间）
November 29, 2018 18:30 – 21:00
Program Rundown （活动流程）:
18:30 – 19:00 Registration
19:00 – 20:30 Presentation and Q&A Session
20:30 – 21:00 Networking
- Member: RMB200
- Non-Member: RMB300
RSVP: Please register by November 27, 2018 请在2018年11月27日前登记
Cancellation of RSVP
In case you need to cancel your attendance to the event, please write an email to: firstname.lastname@example.org
at least 24 hours prior to the event. Failure to cancel your RSVP timely will require the payment of a
“no show bill” of the full amount stated in this invitation. You can contact Nini Qi by telephone: 021 5368 1237. For third-party events, the event terms and conditions of the event organizer apply.
如果您要取消出席活动,请在活动开始前24小时写邮件给 email@example.com。如未能及时取消,我们视同默认付款. 若非瑞士商会主办的活动，取消规则请参照活动主办发布的条款。
Meeting Room, 3F, ATLAS Workplace, Shanghai Agile International Plaza,
525 Xizang Middle Road, Huangpu
黄浦区西藏中路 525 号三楼 寰图